Edrophonum en es it fr

Edrophonum Brand names, Edrophonum Analogs

Edrophonum Brand Names Mixture

  • No information avaliable

Edrophonum Chemical_Formula


Edrophonum RX_link


Edrophonum fda sheet

Edrophonum FDA

Edrophonum msds (material safety sheet)

Edrophonum Synthesis Reference

No information avaliable

Edrophonum Molecular Weight

352.465 g/mol

Edrophonum Melting Point

No information avaliable

Edrophonum H2O Solubility

No information avaliable

Edrophonum State


Edrophonum LogP


Edrophonum Dosage Forms

Powder for solution

Edrophonum Indication

For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

Edrophonum Pharmacology

Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.

Edrophonum Absorption

No information avaliable

Edrophonum side effects and Toxicity

Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.

Edrophonum Patient Information

Edrophonum Organisms Affected

Humans and other mammals